Randomized Trialhigh evidence
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.
Lancet (London, England)·December 20, 2026·PMID 41275875
Why it mattersOrforglipron is an oral, non-peptide GLP-1 receptor agonist, offering a convenient alternative to injectable GLP-1 therapies for weight management in patients with type 2 diabetes. Its efficacy and safety profile support its potential role in expanding treatment options.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled